Brand Name Pharmaceutical Manufacturing in the US - Market Research Report (2014-2029)

Brand name pharmaceutical manufacturers in the US are some of the most lucrative in the world. Consumers in the US use and spend more on prescription drugs than any other country, making manufacturers central to meeting this demand and supporting public health. This role was evident during the COVID-19 pandemic, as brand name pharma producers researched, produced and distributed vital vaccines in record time. Aside from vaccine development, domestic manufacturers can attribute rising spending on brand name drugs to several factors, including an aging population, expanding health coverage, new drug approvals and medical advances in expensive specialty areas like rare diseases and oncology. Still, mounting scrutiny facing brand name pharma makers focuses on pricing policies and patent protections, suggesting that the industry’s strong performance indicates monopolistic practices and price hikes rather than rising prescription drug use. In all, revenue has been growing at a CAGR of 3.7% over the past five years to an estimated $261.2 billion, including expected growth of 1.4% in 2024.

美国知名品牌制药企业是全球最具盈利能力的之一。美国消费者在处方药的使用和消费上远超其他国家，使得制药企业成为满足这一需求和支持公共卫生的关键力量。这一角色在COVID-19大流行期间尤为明显，知名品牌制药生产商在创纪录的时间内进行了疫苗的研究、生产和分发。除了疫苗研发外，国内制造商将品牌药品消费增长归因于诸多因素，包括人口老龄化、健康保险覆盖范围的扩大、新药批准以及昂贵专业领域如罕见病和肿瘤学等医学进步。然而，面对品牌制药生产商日益增加的审查，焦点集中在定价政策和专利保护上，这表明行业的强劲表现更多反映了垄断行为和价格上涨，而非处方药使用量的上升。总体而言，过去五年间，收入以3.7%的复合年增长率增长，预计将达到2612亿美元，其中包括2024年预期的1.4%的增长。